Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Michael Spiegel, deputy director of MATF, said: “In just one year, and with Tecan’s support, we have renovated a whole new space, brought in state-of-the-art, fully automated systems and have them already producing antibodies. This is now the largest capacity and probably the most sophisticated and technologically advanced custom antibody facility in the world. We already have 50 academic projects in the pipeline and we are members of the structural genomic consortium, an international pilot project for creating binding agents to all human proteins and protein binders.“
Most read news
Organizations
Other news from the department science
These products might interest you
Kjel- / Dist Line by Büchi
Kjel- and Dist Line - steam distillation and Kjeldahl applications
Maximum accuracy and performance for your steam distillation and Kjeldahl applications
AZURA Purifier + LH 2.1 by KNAUER
Preparative Liquid Chromatography - New platform for more throughput
Save time and improve reproducibility during purification
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous